Search Bar & Filters
Found 3 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating the use of Vedolizumab in adults with moderate to severely active Ulcerative Colitis UC or Crohns Disease CD. These long-term gut conditions cause symptoms like diarrhea, inflammation, bleeding, and belly pain. The study aims to determine how many participants achieve remission, meaning their symptoms disappear, after 14 weeks of treatment. This is a Phase 4 treatment study sponsored by Takeda. Participants will receive Vedolizumab through two methods. For the first 6 weeks, they get 300 mg intravenously at weeks 0 and 2, with a possible additional dose at week 6. Afterward, starting by week 6 and definitely by week 14, the administration switches to 108 mg injections under the skin every 2 weeks until week 50. Participants who do not respond to treatment by week 14 will stop Vedolizumab and may switch to other treatments, with additional clinic visits at 26 and 52 weeks. A follow-up occurs 18 weeks after the last Vedolizumab dose. Throughout the study, participants have several clinic visits for treatments and assessments. Researchers will measure remission rates using patient-reported outcomes at weeks 6, 14, and 52, alongside clinical response, endoscopic results, and markers like C-reactive protein and fecal calprotectin. Safety is monitored by tracking serious infections up to 72 weeks. The total participation time spans about one year of treatment plus follow-up after treatment ends.
Actively Recruiting
This research aims to evaluate the long-term safety of rimegepant in treating acute migraine attacks in children and adolescents aged 6 to under 18 years. The study focuses on monitoring how well participants tolerate the medication over time and tracking any side effects or safety concerns during treatment. Participants will receive oral doses of rimegepant at 75 mg, 50 mg, or 35 mg as orally disintegrating tablets ODT for acute migraine treatment. This open-label, single-group study follows participants for approximately 58 weeks to assess safety and tolerability, including monitoring liver-related adverse events. Throughout the study, participants will undergo regular assessments including blood sampling and clinical evaluations to monitor adverse events and overall health. Researchers will record the frequency and severity of side effects, serious adverse events, and any lab abnormalities. The total participation duration extends up to 58 weeks, with ongoing safety monitoring during this period.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of BHV-3000 rimegepant compared to a placebo for treating moderate or severe migraine attacks in children and adolescents aged 6 to under 18 years. This Phase 3 study focuses on acute treatment for pediatric migraine, including cases with or without aura, aiming to better understand how well rimegepant relieves migraine pain and associated symptoms shortly after dosing. Participants are randomly assigned to receive either BHV-3000 at doses of 75 mg or 50 mg orally disintegrating tablet ODT or a matching placebo tablet. The study uses a triple-blind design to compare outcomes between these groups. The trial includes children and adolescents who experience 1 to 8 moderate or severe migraine attacks monthly, with attacks lasting over 3 hours. Some participants may continue stable preventive migraine medications except CGRP antagonists. The study monitors patients during the acute migraine attack treatment phase. During the study, participants will be assessed for pain freedom two hours after dosing as the primary outcome, as well as secondary outcomes such as freedom from the most bothersome migraine symptoms, need for rescue medication within 24 to 48 hours, sustained pain freedom, and ability to function normally. Safety and efficacy data will be collected throughout. The total duration of participation varies depending on individual treatment and follow-up requirements, with the primary completion planned by January 2029.